Connor, Clark & Lunn Investment Management (CC&L)’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,088
| Closed | -$115K | – | 1535 |
|
|
2024
Q1 | $115K | Buy |
5,088
+340
| +7% | +$7.7K | ﹤0.01% | 1455 |
|
|
2023
Q4 | $61.6K | Buy |
4,748
+2,396
| +102% | +$31.1K | ﹤0.01% | 1334 |
|
|
2023
Q3 | $47.3K | Sell |
2,352
-147
| -6% | -$2.96K | ﹤0.01% | 1321 |
|
|
2023
Q2 | $67.1K | Sell |
2,499
-9,998
| -80% | -$268K | ﹤0.01% | 1262 |
|
|
2023
Q1 | $729K | Sell |
12,497
-16,322
| -57% | -$952K | ﹤0.01% | 798 |
|
|
2022
Q4 | $1.47M | Buy |
28,819
+18,457
| +178% | +$941K | 0.01% | 618 |
|
|
2022
Q3 | $849K | Buy |
10,362
+7,297
| +238% | +$598K | 0.01% | 693 |
|
|
2022
Q2 | $207K | Buy |
+3,065
| New | +$207K | ﹤0.01% | 932 |
|
|
2019
Q3 | – | Sell |
-3,845
| Closed | -$346K | – | 1023 |
|
|
2019
Q2 | $346K | Sell |
3,845
-4,885
| -56% | -$440K | ﹤0.01% | 796 |
|
|
2019
Q1 | $765K | Buy |
+8,730
| New | +$765K | 0.01% | 585 |
|
|
2016
Q2 | – | Sell |
-1,820
| Closed | -$244K | – | 901 |
|
|
2016
Q1 | $244K | Sell |
1,820
-920
| -34% | -$123K | ﹤0.01% | 687 |
|
|
2015
Q4 | $545K | Buy |
2,740
+68
| +3% | +$13.5K | ﹤0.01% | 526 |
|
|
2015
Q3 | $422K | Sell |
2,672
-375
| -12% | -$59.2K | ﹤0.01% | 550 |
|
|
2015
Q2 | $1.24M | Buy |
3,047
+107
| +4% | +$43.7K | 0.01% | 303 |
|
|
2015
Q1 | $1.35M | Buy |
2,940
+2,207
| +301% | +$1.01M | 0.01% | 274 |
|
|
2014
Q4 | $412K | Buy |
+733
| New | +$412K | ﹤0.01% | 420 |
|